Cyclic Nucleotide Phosphodiesterase 4 Subtypes Are Differentially Expressed by Primary Keratinocytes and Human Epidermoid Cell Lines  by Chujor, Chujor S.N. et al.
Cyclic Nucleotide Phosphodiesterase 4 Subtypes Are
Differentially Expressed by Primary Keratinocytes and Human
Epidermoid Cell Lines
Chujor S.N. Chujor, Franz Hammerschmid,* and Charles Lam
Departments of General Dermatology and *Immunodermatology, Novartis Forschungsinstitut, Vienna, Austria
Cyclic AMP phosphodiesterase (PDE) type 4 has been
the subject of considerable interest as a potential molecu-
lar target for treating cutaneous inflammatory and allergic
disorders; however, little is known regarding the expres-
sion of PDE 4 isogenes in human keratinocytes, the
predominant cell type present in the epidermis. In this
study, we investigated the expression of PDE 4 subtypes
in epidermal cells (primary keratinocytes derived from
breast skin, epidermoid cell lines A431, KB, and HaCaT)
using reverse transcriptase polymerase chain reaction.
Analysis of the amplified cDNA showed that there were
differences in the expression of PDE 4 isogenes in the
epidermal cells. Constitutive expression of the PDE 4
isozymes was detected in untreated epidermal cells at
different levels. Transcripts for PDE 4B and 4D were
abundantly expressed in breast skin-derived ker-
atinocytes, whereas transcripts for PDE 4A, 4C, and 4D
EEpidermal keratinocytes have important immunologicfunctions, as is apparent in allergic and inflammatoryreactions in the skin. In these settings, keratinocytes notonly produce primary proinflammatory cytokines thatattract and modulate lymphocyte functions, but also
respond to other mediators produced by the immune system (Oxholm
et al, 1988; Griffiths et al, 1991; Enk and Katz, 1992; Hunziker et al,
1992; Wood et al, 1992). Epidermal keratinocytes produced tumor
necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) within minutes
or hours upon irradiation with ultraviolet light (Oxholm et al, 1988),
or exposure to irritants (Hunziker et al, 1992) or allergens (Griffiths
et al, 1991; Enk and Katz, 1992). Both TNF-α and IL-1β are potent
proinflammatory mediators that can amplify the release of secondary
cytokines (Nickoloff and Turka, 1993) and induce the expression of
adhesion molecules (Gatto et al, 1992) and major histocompatibility
complex antigens (Waldorf et al, 1991) on endothelial cells. Further
importance of signaling between keratinocytes and other immune cells
is apparent in cutaneous delayed-type hypersensitivity, psoriasis, and
atopic dermatitis (Nickoloff et al, 1991). The importance of primary
proinflammatory cytokines in the development of skin disorders
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were present in HaCaT cells and transcripts for all the
PDE 4 isotypes were present in A431 and KB. PDE 4A
and 4C were detectable in HaCaT cells in equal amounts,
but PDE 4C was only marginally expressed in the other
cells. Of the four isogenes, PDE 4D was abundantly
expressed in all the cells. Elevation of intracellular levels
of cAMP by forskolin increased the expression of all the
hPDE 4 isogenes 2–3-fold as revealed by semiquantitative
reverse transcriptase polymerase chain reaction. Western
blot analysis of extracts from control and forskolin or
dibutyryl cAMP-treated A431 and KB cells demonstrated
the presence of proteins with a molecular mass identical
to that corresponding to recombinant human PDE 4B.
Together, these findings show that PDE 4 isogenes are
expressed in keratinocytes to a different degree and that
their expression can be modulated by intracellular levels
of cAMP. Key words: cAMP/expression/PDE 4 isogenes/RT-
PCR/skin. J Invest Dermatol 110:287–291, 1998
(Fleming, 1993) suggests that inhibition of their production offers an
opportunity to treat inflammatory and immunologic disorders.
One of the many promising approaches to prevent the excessive
production of proinflammatory mediators is the potential utility of
inhibitors of cyclic nucleotide phosphodiesterases (PDE). There are, at
present, seven structurally, biochemically, and pharmacologically distinct
families of cyclic nucleotide phosphodiesterases that are responsible for
controlling the levels of intracellular cyclic nucleotides cAMP and
cGMP (Mu¨ller et al, 1996). Interestingly, PDE type 4 is predominantly
expressed in human myeloid and lymphoid cells (Bolger et al, 1994;
Engels et al, 1994). The family has four gene products (PDE 4A to
PDE 4D) and is characterized by selective, high-affinity hydrolysis of
cAMP and sensitivity to inhibition by rolipram. Inhibition of the
catalytic activity of the isoenzymes increases the levels of intracellular
cAMP with resultant suppression of cell activation (Endres et al, 1991;
De Fraissinette et al, 1992; Chan and Hanifin, 1993). The unique
distribution of the PDE 4 in inflammatory cells, combined with the
central role of these isozymes in regulating the production of primary
cytokines, has generated considerable interest in targeting the enzymes
for potential therapeutic intervention. Indeed, inhibitors of PDE 4
have shown promising pharmacologic effects in a variety of disease
models (Torphy et al, 1994; Banner and Page, 1995; Sekut et al, 1995;
Duplantier et al, 1996). Although results from a number of animal
models of asthma have exemplified that selective PDE 4 inhibitors are
active, there are relatively few studies to support their clinical benefit
in man (Cavalla and Frith, 1995; Hanifin et al, 1996). More importantly,
there is evidence to show that the abnormality seen in atopic individuals
may be due to defects in the cyclic nucleotide regulatory system (Chan
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and Hanifin, 1993), which can be corrected by the use of specific
PDE 4 inhibitors (Hanifin et al, 1996).
Many systems are known to contribute to the inflammatory com-
ponent of atopic skin disorders. It is not clear, however, which PDE
4 isozymes are expressed in the epidermis and whether they contribute,
in part, to the pathogenesis of the disease. An understanding of the
expression and regulation of these isogenes in the epidermis may offer
important clues for the development of PDE 4 subtype-selective
inhibitors. At present there is only circumstantial evidence that ker-
atinocytes, the predominant cells in the skin, express PDE 4 isogenes.
Cultured keratinocytes from normal individuals and patients with
atopic eczema were found to express cAMP phosphodiesterase 4
catalytic activity (Wright et al, 1991). Similar studies reported by Tenor
et al (1995) detected PDE 4 activity in HaCaT cell homogenates and
was found to be modulated by long-term exposure of the cells to
cAMP-elevating agents. Because studies on the catalytic activity of
PDE 4 in cell lines provide little information on the type of PDE 4
isozymes present at the cellular level in vivo, we compared the expression
of PDE 4 isogenes in epidermoid cells and primary keratinocytes using
reverse transcriptase polymerase chain reaction (RT-PCR) and western
blot analysis. We show here that human keratinocytes constitutively
express some of the PDE 4 isozymes. We further show that the
expression of all PDE 4 isozymes can be upregulated by raising the
levels of intracellular cAMP with forskolin.
MATERIALS AND METHODS
Cell culture Epidermal cells (A-431, a human vulva epidermoid cell line;
HaCaT, an immortalized epidermal human keratinocyte cell line; KB, a human
oral cavity epidermoid cell line; and primary keratinocytes prepared from breast
tissue) were plated out at 106 per 20 ml in T-75 culture flasks in endotoxin-
free keratinocyte growth medium (Clonetics, Walkersville, MD) containing
0.06 mM CaCl2 and incubated at 37°C under 5% CO2. At about 70%
confluency, induction of PDE 4 expression was initiated by the addition of
forskolin or dibutyryl cAMP each at 10 µM, as has been previously described
(Engels et al, 1994; Tenor et al, 1995), and the cultures were incubated for a
further 24 h at 37°C.
Isolation of total RNA The spent culture medium was aspirated and total
RNA was prepared by the guanidine isothiocyanate-cesium chloride method
(Chirgrin et al, 1979).
RT-PCR RT-PCR was performed using the BRL superscript preamplifica-
tion system. Five micrograms of total RNA was used for first strand cDNA
synthesis. One-tenth of this reaction mixture was subsequently used for the
polymerase chain reaction (PCR) amplification using Taq DNA polymerase
(Promega, Madison, WI). Specific PCR primers designed for all the four PDE
4 isogenes were used under similar cycle conditions with 2 µCi [α32P]dATP
added to each reaction (30 cycles: 1 min at 95°C, 0.5 min at 60°C, 0.5 min at
72°C). Aliquots of the PCR products were size-fractionated on 3% agarose
gels (Agarose, Sigma, St. Louis, MO), dried, and then exposed to BioMax films
(Kodak, Rochester, NY).
Semi-quantitative RT-PCR was also performed under the same experimental
conditions using human S14 as an internal control. Because of the remarkable
sensitivity of RT-PCR, aliquots were removed after 15, 20, 25, and 30
amplification cycles. After electrophoresis, the agarose was dried and radioactivity
of PCR products was quantitated by an InstantImager (Packard, Meriden, CT).
Specific generic primer pairs as previously published by Engels et al (1994)
and Obernolte et al (1993) were designed and purchased from Vienna Biocenter
(Institute of Microbiology and Genetics, University of Vienna). They were
used to amplify the desired cDNA for PDE 4A/C (440 bp fragment), 59 TCA
GAG CTG GCG CTT ATG TAC 39 (CHD34) and 59 CCG TAT GCT TGT
CAC ACA T 39 (CHD35); PDE 4B (577 bp fragment), 59GCA GAA GAA
TCT TAT CAA AAA TTA GCA ATG 39 (CHD20) and 59 CGT CAG AAT
GGT AAT GGT CTT CTA AAG TC 39 (CHD25); PDE 4D (495 bp
fragment), 59 GCA AGA TCG AGC ACC TAG CA 39 (CHD36) and 59
ACC AGA CAA CTC TGC TAT TC 39 (CHD37); and S14 (143 bp fragment),
59 GGC AGA CCG AGA TGA ATC CTC A 39 (CHD38) and 59 CAG GTC
CAG GGG TCT TGG TCC 39 (CHD39).
Western blot for hPDE 4B protein Monolayers of untreated and dibutyryl
cAMP- or forskolin-treated epidermal cells were lyzed in boiling 2X concen-
trated electrophoresis sample buffer (1X 5 125 Tris-HCl pH 6.8, 2% sodium
dodecyl sulfate, 5% glycerol, 0.003% bromophenol blue, and 1% β-mercapto-
ethanol). The samples were sonicated and centrifuged (10,000 3 g for 5 min)
Figure 1. Expression of PDE 4 isoforms in epidermal keratinocytes
analyzed by RT-PCR. Epidermal cells were cultivated in keratinocyte growth
medium up to 70% confluency, as described under Materials and Methods. Fresh
medium (1, untreated) or fresh medium containing forskolin (10 µM) (2,
forskolin-treated) was added and the cells incubated overnight. PCR was
performed with human PDE 4 isogene specific primer sets on reverse-transcribed
total mRNA. hPDE 4A and C are recognized by the same PCR primers that
give rise to a 440 bp product. The expected size of PCR fragments for hPDE
4B and D are 577 and 495 bp, respectively. The data are representative of
results from more than four experiments.
to remove insoluble material. The protein concentration in a small amount of
the sample was determined using the BCA method (Pierce, Rockford, IL).
Equal amounts of protein (10 µg total protein) were electrophoresed in an
sodium dodecyl sulfate-polyacrylamide gel (mini Protean II, Bio-Rad, Hercules,
CA) and transferred to a polyvinylidene difluoride membrane at 1 A for 1 h.
The membrane was blocked with 5% skim milk in 10 mM Tris-buffered saline
pH 7.5 with 0.1% (vol/vol) Tween 20. Membranes were incubated with rabbit
polyclonal anti-hPDE 4B for 3 h at 37°C in blocking buffer. After three washes
(10 min each), the membranes were incubated for 1 h at room temperature
with anti-rabbit IgG:horseradish peroxidase diluted in 5% nonfat milk in wash
buffer for 1 h at 37°C. The membranes were washed for 1 h with agitation,
changing the wash buffer every 15 min, transferred into bags containing ECL
reagent (Amersham, Bucks, U.K., Cat # RPN 2109), and processed according
to reagent instruction.
RESULTS
Expression of human PDE 4 subtypes by epidermal cells is
upregulated by cAMP-elevating agents Total mRNA from
untreated and forskolin-treated (10 µM) A431, KB, HaCaT, and
primary breast keratinocytes was reverse transcribed into cDNA, and
PCR was performed with isogene-specific pairs of primers. Typical
PDE 4 subtype-specific RT-PCR products detected in untreated and
forskolin-treated single batches of the epidermal cells are shown in
Fig 1. The experiments were repeated more than four times with
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Figure 2. Semi-quantitative RT-PCR analysis of hPDE 4 induction in
HaCaT cells by forskolin, a cAMP-elevating agent. RT-PCR was
performed with total RNA isolated from untreated HaCaT cells (1, untreated)
and treated with forskolin (10 µM) (2, treated) using PDE 4 isogene specific
primers and human S14 ribosomal protein primers (used as an internal control).
The amplified bands are as follows: PDE 4A/C, 440 bp; PDE 4B, 577 bp;
PDE 4D, 495 bp; and S14 ribosomal protein, 143 bp. The data are representative
of results from more than four experiments.
Figure 3. Pattern of expression of hPDE 4 subtypes in epidermal
keratinocytes. RT-PCR was performed with total RNA isolated from the
unstimulated epidermal cells using PDE 4 isogene specific primers. PCR
products of 440 bp derived from CHD34/CHD35 primers (lane 1) were
digested with BstX I (hPDE 4A specific) (lane 2) or EcoRV (hPDE 4C specific)
(lane 3), yielding bands of 330 bp and 110 bp for PDE 4A and 345 bp and
95 bp for PDE 4C. The data are representative of results from more than four
experiments.
other batches of the epidermal cells and we essentially got identical
results. The expected sizes of the PCR fragments were 440 bp
(CHD34/CHD35) for PDE 4A and 4C, 577 bp (CHD20/CHD25)
for 4B, and 495 bp (CHD36/CHD37) for 4D. Transcripts for the
PDE 4 isozymes were detected in untreated epidermal cells at different
intensities. Transcripts for PDE 4B and 4D were detected in breast-
derived keratinocytes, whereas transcripts for PDE 4A/C and 4D were
present in HaCaT cells and transcripts for all the PDE 4 isotypes were
present in A431 and KB. Pretreatment of the epidermal cells with
forskolin (10 µM) for 24 h, resulted in the induction of transcripts for
all the PDE 4 subtypes in all the epidermal cells. The induced mRNA
transcript intensities were about 2–3-fold more than the amounts
detected in untreated cells as revealed by a semiquantitative PCR
performed using a pair of primers specific for human S14 ribosomal
mRNA as an internal control (Fig 2). Equivalent intensities of the
S14-specific bands were detected in both untreated and forskolin-
treated cells, confirming successful normalization of the mRNA. No
PCR product for the S14 was detected in the absence of reverse
transcriptase, suggesting that our RNA preparations were not contamin-
ated with intact DNA.
Human PDE 4 subtypes are expressed to a different degree by
primary keratinocytes and epidermoid cells To analyze more
clearly the subtype distribution of PDE 4 expressed by the four
epidermal cell types, CHD34/CHD35-derived PCR products of
440 bp were digested with restriction enzyme BstX I (hPDE 4A
specific) and EcoRV (hPDE 4C specific) (Fig 3). Digestion products
Figure 4. Western blot analysis of PDE 4 immunoreactivity in epidermal
cell lines A431 and KB using an antibody raised against rat PDE 4B
(DPD). Epidermal cell lines A-431 (left) and KB (right) were either untreated
(lane 1), exposed to 10 µM forskolin (lane 2), or exposed to dibutyryl cAMP
(lane 3) for 24 h. The cells were extensively washed and lysed in sample buffer
containing 2-mercaptoethanol. Equal amounts of protein were subjected to
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and the separated
proteins blotted onto nitrocellulose membranes. The membranes were then
treated as described under Materials and Methods. Immunoreactive PDE 4B was
detected with an antibody raised against rPDE 4B shown previously to cross-
react with hPDE 4 (Engels et al, 1994). The data are representative of results
from two experiments.
characteristic for both hPDE 4A and 4C were obtained in equal
amounts in HaCaT cells. The PCR products of 440 bp obtained from
A431, KB, and primary breast keratinocytes were mainly due to the
expression of hPDE 4A and only marginal amounts of hPDE 4C.
Confirmation of CHD20/CHD25-derived PCR products of 577 bp
as hPDE 4B was obtained by digestion with Msc I. Again, digestion
products of 385 bp and 192 bp that are characteristic of hPDE 4B
were obtained (data not presented). The remaining band of 495 bp
was assumed to be transcripts corresponding to hPDE 4D, as was
previously reported (Engels et al, 1994). These sets of investigations
have been repeated with other batches of the epidermal cells and we
got identical results.
Immunoreactive PDE 4B protein is present in A431 and KB
cell lines To confirm whether the above observed RT-PCR tran-
scripts were translated into proteins, A431 and KB cell lines were
selected for analysis by western blot using a polyclonal anti-serum
raised in rabbits against rat PDE 4B (DPD), previously shown also to
recognize hPDE 4B (Engels et al, 1994). An immunoblot representative
of results from two experiments is presented in Fig 4. One band of
immunoreactivity (µ70 kDa) was detected in both cell lysates with
anti-serum raised against rPDE 4B. This band appeared to slightly
increase in intensity following exposure of the cells to forskolin or
dibutyryl cAMP.
DISCUSSION
PDE type 4 is predominantly expressed in inflammatory cells, including
eosinophils, neutrophils, T lymphocytes, macrophages, and mast cells
(Lugnier and Schini, 1990; Nicholson et al, 1991; Engels et al, 1994).
More importantly, abnormal levels of PDE 4 isoenzymes are considered
to underlie some of the immune and inflammatory abnormalities of
atopic disease (Wright et al, 1991; Chan and Hanifin, 1993; Townley,
1993; Hanifin et al, 1996), suggesting that selective inhibition may
represent a novel approach for treating atopy. Indeed, several studies
have shown that inhibition of this enzyme in vitro by rolipram and
other newer selective inhibitors of PDE 4 suppressed the production
of inflammatory cytokines by activated leukocytes (Endres et al, 1991;
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Berman et al, 1992; Lewis et al, 1993). The predictions from these
in vitro studies have recently been confirmed by showing clinical anti-
inflammatory efficacy of CP-80,633, a potent PDE 4 inhibitor, in
atopic dermatitis patients (Hanifin et al, 1996). Topical application of
CP-80,633 on the skin of 20 patients resulted in a significant reduction
of all inflammatory parameters, without any evidence of side-effects.
Although these studies undoubtedly support the notion that topically
applied PDE 4 inhibitors reduce cytokine and mediator release by
increasing intracellular cAMP levels, thereby suppressing the exagger-
ated atopic responses of immune and inflammatory cells, little is
known about whether PDE 4 inhibitors also affect the functions of
keratinocytes, the predominant cells present in the epidermis.
In this study, we wanted to identify the isogenes of PDE 4 that are
expressed in human epidermal cells and to examine the effect of
elevated intracellular levels of cAMP on the expression of the isozymes.
To address these issues, we monitored the steady-state levels of mRNA
for the PDE 4 isozymes using RT-PCR and analyzed the proteins
expressed using western blot. Our findings show differences in the
patterns of the PDE 4 isozymes that are expressed constitutively
by the various epidermal cells. Breast-derived primary keratinocytes
expressed PDE 4B and 4D constitutively, and HaCaT cells expressed
subtypes 4A, 4C, and 4D. The cell lines A431 and KB expressed all
four subtypes. Exposure of these epidermal cells to forskolin resulted
in induction and expression of all the four subtypes, even by epidermal
cell types that did not express the enzymes constitutively. Levels of the
induced mRNA transcripts were about 2–3-fold over background,
i.e., more than the amounts expressed constitutively. Finally, western
blot analysis of lysates of A431 and KB cells demonstrated the presence
of a protein that reacted with anti-rPDE 4B polyclonal anti-serum.
The immunoreactive protein with anti-rPDE 4B had a molecular
weight identical to that previously determined for the corresponding
recombinant rat or human PDE 4B (Sette et al, 1994). Pre-incubation
of the epidermoid cells with either forskolin or dibutyryl cAMP slightly
upregulated the expression of the protein. There is thus an apparent
discrepancy between the intensities of the amounts of mRNA induced
by cAMP-elevating agents and the amounts of PDE 4B protein detected
in a western blot. One likely reason may be the poor specificity of the
anti-rPDE 4B anti-serum used in this study. Although the anti-serum
has been reported to cross-react with the human proteins (Engels et al,
1994), its degree of cross-reactivity or specificity to react with the
human PDE 4B is unclear. We did not have anti-sera to human PDE
4 isozymes and therefore cannot verify this issue. Nevertheless, the
detection of mRNA transcripts for the PDE 4 isogenes together with
the detection of immunoreactive PDE 4B protein under conditions of
resting or chronic elevation of intracellular cAMP levels, show that
the PDE 4 family are present in epidermal cells and are therefore
potential pharmacologic targets for controlling inflammatory disorders
in the skin.
Our findings regarding PDE responsiveness to elevation of intracellu-
lar levels of cAMP are consistent with studies carried out on human
peripheral blood monocytes and monocytic cell lines (Engels et al,
1994; Torphy et al, 1994; Verghese et al, 1995; Manning et al, 1996).
Constitutive expression of the PDE 4 isogenes by monocytic cells was
either undetectable (Verghese et al, 1995) or low amounts of PDE 4
gene products for PDE 4A, PDE 4B, and PDE 4D were present
(Manning et al, 1996). Chronic elevation of intracellular levels of
cAMP transcriptionally upregulated the expression PDE 4A, PDE 4B,
and PDE 4D in human monocytes and closely related Mono Mac 6
cells (Verghese et al, 1995), but apparently upregulated only PDE 4A
and PDE 4B in human monocytes (Manning et al, 1996) and in U937
monocytic cells (Engels et al, 1994; Torphy et al, 1995). A similar
selective effect of chronic elevation of intracellular levels of cAMP has
been observed in immune cells such as Jurkat T cell lines (Engels et al,
1994; Erdogan and Houslay, 1997). Resting Jurkat cells expressed PDE
4A and PDE 4D but not PDE 4B or PDE 4C. Forskolin treatment
did not induce transcripts for either PDE 4B or PDE 4C; however, it
reduced transcripts for PDE 4A and markedly upregulated the expres-
sion of transcripts for PDE 4D (Erdogan and Houslay, 1997). The
explanation as to why the PDE 4 isogenes in some monocytes and in
Jurkat cells were not affected by elevation of intracellular cAMP
remains to be ascertained. There is a theory that cAMP-responsive
elements determine the expression patterns of PDE 4 subtypes and
variants (Conti et al, 1995). Time-course studies carried out with Mono
Mac 6 cells showed that the induction of PDE 4B by chronic elevation
of intracellular cAMP was transient, with maximal induction occurring
at about 5 h after cAMP elevation (Verghese et al, 1995). It is important
to emphasize that our results represent data obtained at a single time
point. Therefore, it is possible that the induction of PDE 4 isogenes
by chronic elevation of intracellular levels of cAMP in primary
keratinocytes and epidermoid cells at earlier time points, might have
been different from what we have observed at 18–24 h in this study.
The various epidermal cell types used in this study therefore differ
not only in the expression of the total amounts of PDE 4 isozymes,
but also in the relative proportions of the expressed PDE 4 subtypes.
The functional significance of differences in the expression of specific
PDE 4 isogenes in various skin sites remains to be clarified. There are
at present no data in the literature showing the temporal expression
and regulation of PDE 4 subtypes by keratinocytes derived from
various body sites representing different microenvironments. Similarly,
little is known about whether or not the pattern of expression of PDE
4 subtypes changes as highly proliferative basal keratinocytes enter into
a process of terminal differentiation. Nevertheless, our data show that
even within a given cell type, the pattern of constitutively expressed
PDE 4 isogenes at a given time appears to differ. It is unclear to what
extent these differences are due, in part, to the unique microenviron-
ments in the body sites from which the cell lines were derived or to
the degree of their transformation. As studies carried out on human
peripheral blood monocytes and closely related Mono Mac 6 cells
showed that the expression of different PDE 4 subtypes depended on
their state of differentiation and activation and on the conditions
prevailing in their microenvironment (Verghese et al, 1995), it is
tempting to conclude that certain PDE 4 isozymes may be expressed
preferentially over others by epidermal keratinocytes as they proliferate
or differentiate. The expressed isozymes could regulate levels of
intracellular cAMP in an autocrine fashion and thereby play an
important role in regulating the process of keratinocyte differentiation/
proliferation (Crocker et al, 1996; Zurbonsen et al, 1997).
Although we have demonstrated that breast-derived keratinocytes
and epidermoid cell lines express different PDE 4 isozymes, earlier
studies showed that primary keratinocytes and HaCaT cells have only
one PDE 4 catalytic affinity for its substrate (Wright et al, 1991; Tenor
et al, 1995). In contrast, human peripheral blood mononuclear cells
that expressed three (4A, 4B, and 4D) of the four subtypes of PDE 4
exhibited a number of different enzymic catalytic activities, each with
a different affinity for the substrate (Holden and Yuen, 1989). One
explanation for this discrepancy might be that the range of substrate
concentrations used in the studies performed with epidermal cells
(Wright et al, 1991; Tenor et al, 1995) was not sufficient to identify
high Km forms of the enzyme. Further characterization of PDE 4
subtypes in normal and diseased skin is likely to provide the basis for
developing novel PDE 4 isotype-specific pharmacologic agents. Such
hPDE 4 isogene-specific inhibitors may have useful anti-inflammatory
properties with fewer adverse side-effects than inhibitors that affect all
the isoforms.
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